MARKET

TYRA

TYRA

Tyra Biosciences, Inc.
NASDAQ
30.00
-1.40
-4.46%
After Hours: 30.00 0 0.00% 16:32 02/11 EST
OPEN
31.41
PREV CLOSE
31.40
HIGH
32.29
LOW
28.18
VOLUME
951.10K
TURNOVER
--
52 WEEK HIGH
32.44
52 WEEK LOW
6.42
MARKET CAP
1.60B
P/E (TTM)
-15.9608
1D
5D
1M
3M
1Y
5Y
1D
Tyra Biosciences participates in a coferejce call with William Blair
TipRanks · 12h ago
Tyra Biosciences initiated with an Outperform at William Blair
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Tyra Bioscience (TYRA) and Novo Nordisk (NVO)
TipRanks · 1d ago
Weekly Report: what happened at TYRA last week (0202-0206)?
Weekly Report · 2d ago
Tyra Biosciences Advances BEACH301 Dose Escalation
TipRanks · 02/04 16:31
Tyra Biosciences Is Maintained at Outperform by Oppenheimer
Dow Jones · 02/03 15:04
Oppenheimer Maintains Outperform on Tyra Biosciences, Raises Price Target to $50
Benzinga · 02/03 14:54
Tyra Bioscience (TYRA) Gets a Buy from Oppenheimer
TipRanks · 02/03 13:56
More
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.

Webull offers Tyra Biosciences Inc stock information, including NASDAQ: TYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TYRA stock methods without spending real money on the virtual paper trading platform.